Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Hypothyroidism and Risk of Cardiovascular Disease

Author(s): Zoran M. Gluvic*, Sonja S. Zafirovic, Milan M. Obradovic, Emina M. Sudar-Milovanovic, Manfredi Rizzo and Esma R. Isenovic

Volume 28, Issue 25, 2022

Published on: 27 July, 2022

Page: [2065 - 2072] Pages: 8

DOI: 10.2174/1381612828666220620160516

Price: $65

Abstract

Thyroid hormones (TH) have a significant impact on cellular oxidative metabolism. Besides that, they maintain vascular homeostasis by positive effects on endothelial and vascular smooth muscle cells. Subclinical (SCH) and clinical (CH) hypothyroidism influences target organs by changing their morphology and function and impaired blood and oxygen supply induced by accelerated atherosclerosis. The increased risk of acceleration and extension of atherosclerosis in patients with SCH and CH could be explained by dyslipidemia, diastolic hypertension, increased arterial stiffness, endothelial dysfunction, and altered blood coagulation. Instability of atherosclerotic plaque in hypothyroidism could cause excessive activity of the elements of innate immunity, which are characterized by the significant presence of macrophages in atherosclerotic plaques, increased nuclear factor kappa B (NFkB) expression, and elevated levels of tumor necrosis factor α (TNF-α) and matrix metalloproteinase (MMP) 9, with reduced interstitial collagen; all of them together creates inflammation milieu, resulting in plaque rupture. Optimal substitution by levothyroxine (LT4) restores biochemical euthyroidism. In postmenopausal women and elderly patients with hypothyroidism and associated vascular comorbidity, excessive LT4 substitution could lead to atrial rhythm disorders and osteoporosis. Therefore, it is of interest to maintain thyroid-stimulating hormone (TSH) levels in the reference range, thus eliminating the deleterious effects of lower or higher TSH levels on the cardiovascular system. This review summarizes the recent literature on subclinical and clinical hypothyroidism and atherosclerotic cardiovascular disease and discusses the effects of LT4 replacement therapy on restoring biochemical euthyroidism and atherosclerosis processes.

Keywords: Thyroid hormones, hypothyroidism, cardiovascular diseases, atherosclerosis, levothyroxine, biochemical euthyroidism.

« Previous Next »
[1]
Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 2004; 59: 31-50.
[http://dx.doi.org/10.1210/rp.59.1.31] [PMID: 14749496]
[2]
Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation 2010; 122(4): 385-93.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.917922] [PMID: 20660814]
[3]
Tang YD, Kuzman JA, Said S, Anderson BE, Wang X, Gerdes AM. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation 2005; 112(20): 3122-30.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.572883] [PMID: 16275864]
[4]
Razvi S, Jabbar A, Pingitore A, et al. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol 2018; 71(16): 1781-96.
[http://dx.doi.org/10.1016/j.jacc.2018.02.045] [PMID: 29673469]
[5]
Ripoli A, Pingitore A, Favilli B, et al. Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study. J Am Coll Cardiol 2005; 45(3): 439-45.
[http://dx.doi.org/10.1016/j.jacc.2004.10.044] [PMID: 15680725]
[6]
Biondi B, Palmieri EA, Lombardi G, Fazio S. Subclinical hypothyroidism and cardiac function. Thyroid 2002; 12(6): 505-10.
[http://dx.doi.org/10.1089/105072502760143890] [PMID: 12165114]
[7]
Biondi B. Cardiovascular effects of mild hypothyroidism. Thyroid 2007; 17(7): 625-30.
[http://dx.doi.org/10.1089/thy.2007.0158] [PMID: 17696831]
[8]
Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004; 363(9411): 793-803.
[http://dx.doi.org/10.1016/S0140-6736(04)15696-1] [PMID: 15016491]
[9]
Brenta G, Mutti LA, Schnitman M, Fretes O, Perrone A, Matute ML. Assessment of left ventricular diastolic function by radionuclide ventriculography at rest and exercise in subclinical hypothyroidism, and its response to L-thyroxine therapy. Am J Cardiol 2003; 91(11): 1327-30.
[http://dx.doi.org/10.1016/S0002-9149(03)00322-9] [PMID: 12767425]
[10]
Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344(7): 501-9.
[http://dx.doi.org/10.1056/NEJM200102153440707] [PMID: 11172193]
[11]
Park KW, Dai HB, Ojamaa K, Lowenstein E, Klein I, Sellke FW. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg 1997; 85(4): 734-8.
[http://dx.doi.org/10.1213/00000539-199710000-00005] [PMID: 9322448]
[12]
Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid 1996; 6(5): 505-12.
[http://dx.doi.org/10.1089/thy.1996.6.505] [PMID: 8936680]
[13]
Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 1995; 333(23): 1522-7.
[http://dx.doi.org/10.1056/NEJM199512073332302] [PMID: 7477166]
[14]
Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012; 379(9821): 1142-54.
[http://dx.doi.org/10.1016/S0140-6736(11)60276-6] [PMID: 22273398]
[15]
Rodondi N, Newman AB, Vittinghoff E, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 2005; 165(21): 2460-6.
[http://dx.doi.org/10.1001/archinte.165.21.2460] [PMID: 16314541]
[16]
Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 2010; 304(12): 1365-74.
[http://dx.doi.org/10.1001/jama.2010.1361] [PMID: 20858880]
[17]
Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: A metaanalysis. J Clin Endocrinol Metab 2008; 93(8): 2998-3007.
[http://dx.doi.org/10.1210/jc.2008-0167] [PMID: 18505765]
[18]
Einfeldt MN, Olsen AS, Kristensen SL, et al. Long-term outcome in patients with heart failure treated with levothyroxine: An observational nationwide cohort study. J Clin Endocrinol Metab 2019; 104(5): 1725-34.
[http://dx.doi.org/10.1210/jc.2018-01604] [PMID: 30517746]
[19]
Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet 2017; 390(10101): 1550-62.
[http://dx.doi.org/10.1016/S0140-6736(17)30703-1] [PMID: 28336049]
[20]
Aziz M, Kandimalla Y, Machavarapu A, et al. Effect of thyroxin treatment on carotid intima-media thickness (CIMT) reduction in patients with subclinical hypothyroidism (SCH): A meta-analysis of clinical trials. J Atheroscler Thromb 2017; 24(7): 643-59.
[http://dx.doi.org/10.5551/jat.39917] [PMID: 28566564]
[21]
Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: Beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003; 88(8): 3731-7.
[http://dx.doi.org/10.1210/jc.2003-030039] [PMID: 12915662]
[22]
Biondi B, Klein I. Hypothyroidism as a risk factor for cardiovascular disease. Endocrine 2004; 24(1): 1-13.
[http://dx.doi.org/10.1385/ENDO:24:1:001] [PMID: 15249698]
[23]
Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab 2010; 95(1): 186-93.
[http://dx.doi.org/10.1210/jc.2009-1625] [PMID: 19906785]
[24]
Gluvic Z, Obradovic M, Stewart AJ, et al. Levothyroxine treatment and the risk of cardiac arrhythmias - focus on the patient submitted to thyroid surgery. Front Endocrinol (Lausanne) 2021; 12: 758043.
[http://dx.doi.org/10.3389/fendo.2021.758043] [PMID: 34803920]
[25]
van der Spek AH, Fliers E, Boelen A. Thyroid hormone metabolism in innate immune cells. J Endocrinol 2017; 232(2): R67-81.
[http://dx.doi.org/10.1530/JOE-16-0462] [PMID: 27852725]
[26]
Giammanco M, Di Liegro CM, Schiera G, Di Liegro I. Genomic and non-genomic mechanisms of action of thyroid hormones and their catabolite 3,5-Diiodo-L-Thyronine in mammals. Int J Mol Sci 2020; 21(11): 4140.
[http://dx.doi.org/10.3390/ijms21114140] [PMID: 32532017]
[27]
Forini F, Nicolini G, Kusmic C, et al. T3 critically affects the Mhrt/Brg1 axis to regulate the cardiac MHC switch: Role of an epigenetic cross-talk. Cells 2020; 9(10): 9.
[http://dx.doi.org/10.3390/cells9102155] [PMID: 32987653]
[28]
Forini F, Nicolini G, Kusmic C, Iervasi G. Protective effects of euthyroidism restoration on mitochondria function and quality control in cardiac pathophysiology. Int J Mol Sci 2019; 20(14): 3377.
[http://dx.doi.org/10.3390/ijms20143377] [PMID: 31295805]
[29]
Udovcic M, Pena RH, Patham B, Tabatabai L, Kansara A. Hypothyroidism and the heart. Methodist DeBakey Cardiovasc J 2017; 13(2): 55-9.
[http://dx.doi.org/10.14797/mdcj-13-2-55] [PMID: 28740582]
[30]
Davis PJ, Goglia F, Leonard JL. Nongenomic actions of thyroid hormone. Nat Rev Endocrinol 2016; 12(2): 111-21.
[http://dx.doi.org/10.1038/nrendo.2015.205] [PMID: 26668118]
[31]
Karthick N, Dillara K, Poornima KN, Subhasini AS. Dyslipidaemic changes in women with subclinical hypothyroidism. J Clin Diagn Res 2013; 7(10): 2122-5.
[http://dx.doi.org/10.7860/JCDR/2013/5777.3448] [PMID: 24298454]
[32]
Valentina VN, Marijan B, Chedo D, Branka K. Subclinical hypothyroidism and risk to carotid atherosclerosis. Arq Bras Endocrinol Metabol 2011; 55(7): 475-80.
[http://dx.doi.org/10.1590/S0004-27302011000700007] [PMID: 22147096]
[33]
Gao C, Li T, Liu J, Guo Q, Tian L. Endothelial functioning and hemodynamic parameters in rats with subclinical hypothyroid and the effects of thyroxine replacement. PLoS One 2015; 10(7): e0131776.
[http://dx.doi.org/10.1371/journal.pone.0131776] [PMID: 26158620]
[34]
Obradovic M, Gluvic Z, Sudar-Milovanovic E, et al. Nitric oxide as a marker for levo-thyroxine therapy in subclinical hypothyroid patients. Curr Vasc Pharmacol 2016; 14(3): 266-70.
[http://dx.doi.org/10.2174/1570161114666160208143537] [PMID: 26853795]
[35]
Kannan L, Shaw PA, Morley MP, et al. Thyroid dysfunction in heart failure and cardiovascular outcomes. Circ Heart Fail 2018; 11(12): e005266.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.118.005266] [PMID: 30562095]
[36]
Dong J, Gao C, Liu J, Cao Y, Tian L. TSH inhibits SERCA2a and the PKA/PLN pathway in rat cardiomyocytes. Oncotarget 2016; 7(26): 39207-15.
[http://dx.doi.org/10.18632/oncotarget.9393] [PMID: 27206677]
[37]
Chen X, Gao C, Gong N, Wang Y, Tian L. The change of left ventricular function in rats with subclinical hypothyroid and the effects of thyroxine replacement. Int J Endocrinol 2018; 2018: 8682765.
[http://dx.doi.org/10.1155/2018/8682765] [PMID: 29686704]
[38]
Gong N, Gao C, Chen X, Wang Y, Tian L. Adipokine expression and endothelial function in subclinical hypothyroidism rats. Endocr Connect 2018; 7(2): 295-304.
[http://dx.doi.org/10.1530/EC-18-0007] [PMID: 29440225]
[39]
Xue D, Sun JL, Yang J. Early L-T4 intervention improves fetal heart development in pregnant rats with subclinical hypothyroidism rats by activating BMP4/Smad4 signaling pathway. BMC Cardiovasc Disord 2020; 20(1): 369.
[http://dx.doi.org/10.1186/s12872-020-01646-3] [PMID: 32795258]
[40]
Tunbridge WM, Evered DC, Hall R, et al. Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failure. Clin Endocrinol (Oxf) 1977; 7(6): 495-508.
[http://dx.doi.org/10.1111/j.1365-2265.1977.tb01341.x] [PMID: 598015]
[41]
Vanderpump MP, Tunbridge WM, French JM, et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 1996; 6(3): 155-60.
[PMID: 8837320]
[42]
Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The rotterdam study. Ann Intern Med 2000; 132(4): 270-8.
[http://dx.doi.org/10.7326/0003-4819-132-4-200002150-00004] [PMID: 10681281]
[43]
Staub JJ, Althaus BU, Engler H, et al. Spectrum of subclinical and overt hypothyroidism: Effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med 1992; 92(6): 631-42.
[http://dx.doi.org/10.1016/0002-9343(92)90782-7] [PMID: 1605145]
[44]
Heinonen OP, Gordin A, Aho K, Punsar S, Pyörälä K, Puro K. Symptomless autoimmune thyroiditis in coronary heart-disease. Lancet 1972; 1(7754): 785-6.
[http://dx.doi.org/10.1016/S0140-6736(72)90534-X] [PMID: 4111258]
[45]
Imaizumi M, Akahoshi M, Ichimaru S, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab 2004; 89(7): 3365-70.
[http://dx.doi.org/10.1210/jc.2003-031089] [PMID: 15240616]
[46]
Biondi B. Natural history, diagnosis and management of subclinical thyroid dysfunction. Best Pract Res Clin Endocrinol Metab 2012; 26(4): 431-46.
[http://dx.doi.org/10.1016/j.beem.2011.12.004] [PMID: 22863386]
[47]
Asvold BO, Bjøro T, Nilsen TI, Gunnell D, Vatten LJ. Thyrotropin levels and risk of fatal coronary heart disease: The HUNT study. Arch Intern Med 2008; 168(8): 855-60.
[http://dx.doi.org/10.1001/archinte.168.8.855] [PMID: 18443261]
[48]
Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 2005; 165(21): 2467-72.
[http://dx.doi.org/10.1001/archinte.165.21.2467] [PMID: 16314542]
[49]
Boekholdt SM, Titan SM, Wiersinga WM, et al. Initial thyroid status and cardiovascular risk factors: The EPIC-Norfolk prospective population study. Clin Endocrinol (Oxf) 2010; 72(3): 404-10.
[http://dx.doi.org/10.1111/j.1365-2265.2009.03640.x] [PMID: 19486022]
[50]
Surks MI, Ocampo E. Subclinical thyroid disease. Am J Med 1996; 100(2): 217-23.
[http://dx.doi.org/10.1016/S0002-9343(97)89462-4] [PMID: 8629658]
[51]
Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: Response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab 2002; 87(4): 1533-8.
[http://dx.doi.org/10.1210/jcem.87.4.8378] [PMID: 11932277]
[52]
Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid 2000; 10(9): 803-8.
[http://dx.doi.org/10.1089/thy.2000.10.803] [PMID: 11041458]
[53]
Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 2000; 10(8): 665-79.
[http://dx.doi.org/10.1089/10507250050137743] [PMID: 11014311]
[54]
Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: A quantitative review of the literature. J Clin Endocrinol Metab 2000; 85(9): 2993-3001.
[PMID: 10999775]
[55]
Geul KW, van Sluisveld IL, Grobbee DE, et al. The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle-aged women: Associations with serum lipids. Clin Endocrinol 1993; 39(3): 275-80.
[http://dx.doi.org/10.1111/j.1365-2265.1993.tb02366.x] [PMID: 8222290]
[56]
Parle JV, Franklyn JA, Cross KW, Jones SR, Sheppard MC. Circulating lipids and minor abnormalities of thyroid function. Clin Endocrinol 1992; 37(5): 411-4.
[http://dx.doi.org/10.1111/j.1365-2265.1992.tb02351.x] [PMID: 1486690]
[57]
Kung AW, Pang RW, Janus ED. Elevated serum lipoprotein(a) in subclinical hypothyroidism. Clin Endocrinol 1995; 43(4): 445-9.
[http://dx.doi.org/10.1111/j.1365-2265.1995.tb02616.x] [PMID: 7586619]
[58]
Yildirimkaya M, Ozata M, Yilmaz K, Kilinç C, Gündoğan MA, Kutluay T. Lipoprotein(a) concentration in subclinical hypothyroidism before and after levo-thyroxine therapy. Endocr J 1996; 43(6): 731-6.
[http://dx.doi.org/10.1507/endocrj.43.731] [PMID: 9075615]
[59]
Monzani F, Caraccio N, Kozàkowà M, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: A double-blind, placebo- controlled study. J Clin Endocrinol Metab 2004; 89(5): 2099-106.
[http://dx.doi.org/10.1210/jc.2003-031669] [PMID: 15126526]
[60]
Arem R, Escalante DA, Arem N, Morrisett JD, Patsch W. Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a). Metabolism 1995; 44(12): 1559-63.
[http://dx.doi.org/10.1016/0026-0495(95)90075-6] [PMID: 8786724]
[61]
Meier C, Staub JJ, Roth CB, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: A double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001; 86(10): 4860-6.
[http://dx.doi.org/10.1210/jcem.86.10.7973] [PMID: 11600554]
[62]
Pazos F, Alvarez JJ, Rubiés-Prat J, Varela C, Lasunción MA. Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J Clin Endocrinol Metab 1995; 80(2): 562-6.
[PMID: 7852521]
[63]
Marfella R, Ferraraccio F, Rizzo MR, et al. Innate immune activity in plaque of patients with untreated and L-thyroxine-treated subclinical hypothyroidism. J Clin Endocrinol Metab 2011; 96(4): 1015-20.
[http://dx.doi.org/10.1210/jc.2010-1382] [PMID: 21239513]
[64]
Salonen RM, Nyyssönen K, Kaikkonen J, et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: The Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 2003; 107(7): 947-53.
[http://dx.doi.org/10.1161/01.CIR.0000050626.25057.51] [PMID: 12600905]
[65]
Erenus M, Ilhan AH, Elter K. Effect of tibolone treatment on intima-media thickness and the resistive indices of the carotid arteries. Fertil Steril 2003; 79(2): 268-73.
[http://dx.doi.org/10.1016/S0015-0282(02)04580-6] [PMID: 12568833]
[66]
Gluvic Z, Sudar E, Tica J, et al. Effects of levothyroxine replacement therapy on parameters of metabolic syndrome and atherosclerosis in hypothyroid patients: A prospective pilot study. Int J Endocrinol 2015; 2015: 147070.
[http://dx.doi.org/10.1155/2015/147070] [PMID: 25821465]
[67]
Mizuma H, Murakami M, Mori M. Thyroid hormone activation in human vascular smooth muscle cells: Expression of type II iodothyronine deiodinase. Circ Res 2001; 88(3): 313-8.
[http://dx.doi.org/10.1161/01.RES.88.3.313] [PMID: 11179199]
[68]
Weber T, Auer J, O’Rourke MF, et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 2004; 109(2): 184-9.
[http://dx.doi.org/10.1161/01.CIR.0000105767.94169.E3] [PMID: 14662706]
[69]
Galli E, Pingitore A, Iervasi G. The role of thyroid hormone in the pathophysiology of heart failure: Clinical evidence. Heart Fail Rev 2010; 15(2): 155-69.
[http://dx.doi.org/10.1007/s10741-008-9126-6] [PMID: 19110971]
[70]
Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol 2010; 6(8): 431-43.
[http://dx.doi.org/10.1038/nrendo.2010.105] [PMID: 20585347]
[71]
Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 2003; 88(6): 2438-44.
[http://dx.doi.org/10.1210/jc.2003-030398] [PMID: 12788839]
[72]
Wang K, Ojamaa K, Samuels A, et al. BNP as a new biomarker of cardiac thyroid hormone function. Front Physiol 2020; 11: 729.
[http://dx.doi.org/10.3389/fphys.2020.00729] [PMID: 32733267]
[73]
Chuhray SN, Lavrynenko VE, Kaminsky RF, et al. Cardiovascular system of the mature rats with congenital hypothyroidism and arterial hypertension. Wiad Lek 2020; 73(10): 2209-13.
[http://dx.doi.org/10.36740/WLek202010119] [PMID: 33310949]
[74]
Ghanbari M, Norouzirad R, Bagheripuor F, Jeddi S, Ghasemi A. Changes in nitric oxide synthase levels are associated with impaired cardiac function and tolerance to ischemia-reperfusion injury in male rats with transient congenital hypothyroidism. Naunyn Schmiedebergs Arch Pharmacol 2020; 393(6): 1103-11.
[http://dx.doi.org/10.1007/s00210-020-01812-6] [PMID: 31940052]
[75]
Bengel FM, Nekolla SG, Ibrahim T, Weniger C, Ziegler SI, Schwaiger M. Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging. J Clin Endocrinol Metab 2000; 85(5): 1822-7.
[http://dx.doi.org/10.1210/jcem.85.5.6520] [PMID: 10843159]
[76]
Vanhaelst L, Neve P, Chailly P, Bastenie PA. Coronary-artery disease in hypothyroidism. Observations in clinical myxoedema. Lancet 1967; 2(7520): 800-2.
[http://dx.doi.org/10.1016/S0140-6736(67)92235-0] [PMID: 4167274]
[77]
Steinberg AD. Myxedema and coronary artery disease--a comparative autopsy study. Ann Intern Med 1968; 68(2): 338-44.
[http://dx.doi.org/10.7326/0003-4819-68-2-338] [PMID: 5713917]
[78]
Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol 2017; 14(1): 39-55.
[http://dx.doi.org/10.1038/nrcardio.2016.174] [PMID: 27811932]
[79]
Walton KW, Scott PJ, Dykes PW, Davies JW. The significance of alterations in serum lipids in thyroid dysfunction. II. Alterations of the metabolism and turnover of 131-I-low-density lipoproteins in hypothyroidism and thyrotoxicosis. Clin Sci 1965; 29(2): 217-38.
[PMID: 5840973]
[80]
Salter AM, Hayashi R, al-Seeni M, et al. Effects of hypothyroidism and high-fat feeding on mRNA concentrations for the low-density-lipoprotein receptor and on acyl-CoA:cholesterol acyltransferase activities in rat liver. Biochem J 1991; 276(Pt 3): 825-32.
[http://dx.doi.org/10.1042/bj2760825] [PMID: 2064617]
[81]
Staels B, Van Tol A, Chan L, Will H, Verhoeven G, Auwerx J. Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low density lipoprotein receptor in rats. Endocrinology 1990; 127(3): 1144-52.
[http://dx.doi.org/10.1210/endo-127-3-1144] [PMID: 2387252]
[82]
Sundaram V, Hanna AN, Koneru L, Newman HA, Falko JM. Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation. J Clin Endocrinol Metab 1997; 82(10): 3421-4.
[PMID: 9329379]
[83]
Diekman T, Demacker PN, Kastelein JJ, Stalenhoef AF, Wiersinga WM. Increased oxidizability of low-density lipoproteins in hypothyroidism. J Clin Endocrinol Metab 1998; 83(5): 1752-5.
[http://dx.doi.org/10.1210/jcem.83.5.4759] [PMID: 9589687]
[84]
Becerra A, Bellido D, Luengo A, Piédrola G, De Luis DA. Lipoprotein(a) and other lipoproteins in hypothyroid patients before and after thyroid replacement therapy. Clin Nutr 1999; 18(5): 319-22.
[http://dx.doi.org/10.1016/S0261-5614(98)80031-9] [PMID: 10601541]
[85]
Weintraub M, Grosskopf I, Trostanesky Y, Charach G, Rubinstein A, Stern N. Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism. J Clin Endocrinol Metab 1999; 84(7): 2532-6.
[http://dx.doi.org/10.1210/jcem.84.7.5812] [PMID: 10404832]
[86]
Ritter MC, Kannan CR, Bagdade JD. The effects of hypothyroidism and replacement therapy on cholesteryl ester transfer. J Clin Endocrinol Metab 1996; 81(2): 797-800.
[PMID: 8636306]
[87]
Lam KS, Chan MK, Yeung RT. High-density lipoprotein cholesterol, hepatic lipase and lipoprotein lipase activities in thyroid dysfunction--effects of treatment. Q J Med 1986; 59(229): 513-21.
[PMID: 3763814]
[88]
Müller B, Zulewski H, Huber P, Ratcliffe JG, Staub JJ. Impaired action of thyroid hormone associated with smoking in women with hypothyroidism. N Engl J Med 1995; 333(15): 964-9.
[http://dx.doi.org/10.1056/NEJM199510123331503] [PMID: 7666915]
[89]
Thayakaran R, Adderley NJ, Sainsbury C, et al. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: Longitudinal study. BMJ 2019; 366: l4892.
[http://dx.doi.org/10.1136/bmj.l4892] [PMID: 31481394]
[90]
Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23(2): 168-75.
[http://dx.doi.org/10.1161/01.ATV.0000051384.43104.FC] [PMID: 12588755]
[91]
Rajagopalan V, Zhang Y, Pol C, et al. Modified low-dose triiodo-l-thyronine therapy safely improves function following myocardial ischemia-reperfusion injury. Front Physiol 2017; 8: 225.
[http://dx.doi.org/10.3389/fphys.2017.00225] [PMID: 28446882]
[92]
Rajagopalan V, Zhang Y, Ojamaa K, et al. Safe oral triiodo-L-thyronine therapy protects from post-infarct cardiac dysfunction and arrhythmias without cardiovascular adverse effects. PLoS One 2016; 11(3): e0151413.
[http://dx.doi.org/10.1371/journal.pone.0151413] [PMID: 26981865]
[93]
Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: Randomized, crossover trial. J Clin Endocrinol Metab 2007; 92(5): 1715-23.
[http://dx.doi.org/10.1210/jc.2006-1869] [PMID: 17299073]
[94]
Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: A prospective study. Circulation 2002; 105(13): 1567-72.
[http://dx.doi.org/10.1161/01.CIR.0000012543.55874.47] [PMID: 11927524]
[95]
Pyke KE, Tschakovsky ME. The relationship between shear stress and flow-mediated dilatation: Implications for the assessment of endothelial function. J Physiol 2005; 568(Pt 2): 357-69.
[http://dx.doi.org/10.1113/jphysiol.2005.089755] [PMID: 16051630]
[96]
Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Part 2. Ann Intern Med 1996; 124(5): 518-31.
[http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00013] [PMID: 8602715]
[97]
Zanchetti A, Bond MG, Hennig M, et al. Risk factors associated with alterations in carotid intima-media thickness in hypertension: Baseline data from the European lacidipine study on atherosclerosis. J Hypertens 1998; 16(7): 949-61.
[http://dx.doi.org/10.1097/00004872-199816070-00008] [PMID: 9794735]
[98]
Christ-Crain M, Meier C, Guglielmetti M, et al. Elevated C-reactive protein and homocysteine values: Cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003; 166(2): 379-86.
[http://dx.doi.org/10.1016/S0021-9150(02)00372-6] [PMID: 12535752]

Rights & Permissions Print Cite
Article Metrics
27
1
© 2024 Bentham Science Publishers | Privacy Policy